NCT00718679已完成1 期
Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Saftety tolerability and efficacy
研究概览
简要总结
This study is placebo controlled, double blind, randomised, two arm dose escalation of a new product for specific immunotherapy in cat allergic patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
Study drug
干预措施: IVN201 (Drug)
2
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Saftety tolerability and efficacy
时间窗: 2009
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of VIS410 to Assess Safety and PharmacokineticsInfluenzaNCT02045472Visterra, Inc.41
已完成
2 期
Study of Live Attenuated ChimeriVax™-Japanese Encephalitis VaccineJapanese EncephalitisNCT00981630Sanofi128
已完成
1 期
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy ParticipantsVirus, ZikaFlavivirus InfectionsHealthy ParticipantsZika Virus DiseaseNCT03343626Takeda271
已完成
1 期
A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy VolunteersHealthyNCT03156738Mitsubishi Tanabe Pharma Corporation40
已完成
1 期
A Safety Study of TTP4000 in Subjects With Alzheimer's DiseaseAlzheimer's DiseaseNCT01548430vTv Therapeutics8